What is the Mersana Therapeutics Inc. stock price forecast?

Mersana Therapeutics Inc. is currently trading at $29.08. View real-time AI analysis on Alpha Lenz.

What is Mersana Therapeutics Inc. insider trading activity?

View the latest insider trading data for Mersana Therapeutics Inc. on Alpha Lenz.

What is Mersana Therapeutics Inc.'s P/E ratio?

Mersana Therapeutics Inc.'s P/E ratio is -2.1.

Mersana Therapeutics Inc.

NASDAQ · MRSN

$29.08+0.00(+0.00%)Market closed

Ask about Mersana Therapeutics Inc.'s future dividend policy...

Alpha Chat Insight

“Mersana Therapeutics Inc. trades at a P/E of -2.1 (undervalued) with modest ROE of -505.1%. 3Y revenue CAGR of 880.2% highlights clear growth momentum.”

Ask for details →

Company Overview

Mersana Therapeutics Inc. is a biotechnology company specializing in the development of advanced antibody-drug conjugates (ADCs) aimed at improving cancer treatment outcomes. The company focuses on innovating and optimizing ADC technology to create therapies that are more targeted and effective in attacking cancer cells while minimizing damage to healthy tissues. Mersana's proprietary platforms, like Dolaflexin and Dolasynthen, are designed to enhance the delivery and potency of therapeutic compounds, thereby addressing unmet needs in oncology. The company is actively involved in clinical trials and collaborations with pharmaceutical industry leaders to advance its pipeline of investigational drugs. By pioneering novel access points in oncological biotechnology, Mersana Therapeutics plays a significant role in the pharmaceutical and healthcare sectors, offering potential breakthroughs in cancer care and treatment.

CEODr. Martin H. Huber M.D.

Websitehttps://www.mersana.com

SectorHealthcare

IndustryBiotechnology

Employees102

Company Statistics

FY 2024

Profile

$142.54MMarket Cap

$40.50MRevenue

0.00Shares Out

102Employees

Margins

N/AGross

-156.24%EBITDA

-181.09%Operating

-169.82%Pre-Tax

-170.86%Net

Valuation

-2.06P/E

-14.99P/B

3.52EV/Sales

-1.00EV/EBITDA

-1.73P/FCF

Growth (CAGR)

880.21%Rev 3Yr

-0.78%Rev 5Yr

N/AOp Inc 3Yr

N/AOp Inc 5Yr

N/ANet Inc 3Yr

N/ANet Inc 5Yr

Returns

-37.33%ROA

-505.14%ROE

-35.01%ROIC

Financial Health

$107.75MCash & Cash Equivalents

$46.42MNet Debt

-1621.33%Debt/Equity

N/AInterest Cov

Alpha Chat Insight

“Mersana Therapeutics Inc. trades at a P/E of -2.1 (undervalued) with modest ROE of -505.1%. 3Y revenue CAGR of 880.2% highlights clear growth momentum.”

Ask for details →

Frequently Asked Questions

Mersana Therapeutics Inc. (ticker: MRSN) is a company listed on NASDAQ in the Healthcare sector (Biotechnology). It has approximately 102 employees. Market cap is $143M.

The current price is $29.08 with a P/E ratio of -2.06x and P/B of -14.99x.

ROE is -505.14% and operating margin is -181.09%. Annual revenue is $40M.